CCP
AMED

Corient Capital Partners’s Amedisys AMED Stock Holding History

Corient Capital Partners’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,730
Closed -$424K – 695
2021
Q2 		$424K Buy
1,730
+15
+0.9% +$3.94K 0.03% 398
2021
Q1 		$454K Buy
+1,715
New +$484K 0.04% 336

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Corient Capital Partners's AMED Position: Q3 2021 in Review

Corient Capital Partners sold out of Amedisys (AMED) in Q3 2021, closing a stake of 1,730 shares — an estimated $424K sold.

Corient Capital Partners first reported a position in AMED in Q1 2021 and held it in 2 quarters. The position peaked at $454K in Q1 2021. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Corient Capital Partners reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Corient Capital Partners sold 1,730 Amedisys shares in Q3 2021, an estimated $424K.
  • Corient Capital Partners first reported a position in Amedisys in Q1 2021 and held it in 2 quarters.
  • Corient Capital Partners's Amedisys position peaked at $454K in Q1 2021.
  • 351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Corient Capital Partners's 13F filing for Q3 2021, filed 16 Nov 2021.